Scholarlink

Background <p>Bronchiectasis is commonly considered a disease of older adults, with advancing age associated with greater disease severity and poorer clinical outcomes. However, whether younger patients represent a genuinely low-risk phenotype characterized by fewer exacerbations, reduced hospitalization burden, preserved lung function, and lower mortality risk remains uncertain.</p> Methods <p>We conducted a retrospective cohort study using data from the Taiwan Bronchiectasis Research Collaboration, a nationwide multicenter registry. Adult patients with non-cystic fibrosis bronchiectasis were stratified according to age at enrollment into three groups: &lt; 50&#xa0;years, 50–69&#xa0;years, and ≥ 70&#xa0;years. Acute exacerbations, hospitalizations, overall survival, and longitudinal changes in pulmonary function were compared among the age groups.</p> Results <p>Among 2753 patients, increasing age was associated with a higher comorbidity burden, poorer baseline lung function, and lower overall survival. Although most patients across all age groups did not experience exacerbations, the proportion of frequent exacerbators requiring hospitalization (≥ 2 hospitalizations per year) was comparable between patients aged &lt; 50&#xa0;years and those aged ≥ 70&#xa0;years. Compared with patients aged 50–69&#xa0;years, those aged &lt; 50&#xa0;years had a significantly higher risk of recurrent hospitalization. Longitudinal analyses demonstrated the greatest absolute declines in pre-bronchodilator forced expiratory volume in 1&#xa0;s and forced vital capacity among patients aged &lt; 50&#xa0;years, with a trend toward greater FEV<sub>1</sub> decline, whereas lung function remained relatively stable in the older age groups.</p> Conclusions <p>In this nationwide cohort, younger patients exhibited clinically meaningful disease activity, including recurrent hospitalization and greater longitudinal lung function decline, despite fewer comorbidities and better baseline lung function. These findings underscore the heterogeneity of bronchiectasis and suggest that younger age does not necessarily indicate a benign disease course.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Age-related differences in clinical outcomes and lung function trajectories in noncystic fibrosis bronchiectasis: a multicenter TBARC registry study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月12日

查看全文
  • Wen-Chien Cheng,
  • Chia-Ling Chang,
  • Chau-Chyun Sheu,
  • Ping-Huai Wang,
  • Meng-Heng Hsieh,
  • Ming-Tsung Chen,
  • Wei-Fan Ou,
  • Yu-Feng Wei,
  • Tsung-Ming Yang,
  • Chou-Chin Lan,
  • Cheng-Yi Wang,
  • Chih-Bin Lin,
  • Ming-Shian Lin,
  • Yao-Tung Wang,
  • Ching-Hsiung Lin,
  • Shih-Feng Liu,
  • Meng-Hsuan Cheng,
  • Yen-Fu Chen,
  • Chung-Kan Peng,
  • Ming-Cheng Chan,
  • Ching-Yi Chen,
  • Lun-Yu Jao,
  • Ya-Hui Wang,
  • Yung-Hsuan Wang,
  • Shih-Pin Chen,
  • Yi-Hsuan Tsai,
  • Shih-Lung Cheng,
  • Horng-Chyuan Lin,
  • Jung-Yien Chien,
  • Hao-Chien Wang,
  • Wu-Huei Hsu

摘要

Background

Bronchiectasis is commonly considered a disease of older adults, with advancing age associated with greater disease severity and poorer clinical outcomes. However, whether younger patients represent a genuinely low-risk phenotype characterized by fewer exacerbations, reduced hospitalization burden, preserved lung function, and lower mortality risk remains uncertain.

Methods

We conducted a retrospective cohort study using data from the Taiwan Bronchiectasis Research Collaboration, a nationwide multicenter registry. Adult patients with non-cystic fibrosis bronchiectasis were stratified according to age at enrollment into three groups: < 50 years, 50–69 years, and ≥ 70 years. Acute exacerbations, hospitalizations, overall survival, and longitudinal changes in pulmonary function were compared among the age groups.

Results

Among 2753 patients, increasing age was associated with a higher comorbidity burden, poorer baseline lung function, and lower overall survival. Although most patients across all age groups did not experience exacerbations, the proportion of frequent exacerbators requiring hospitalization (≥ 2 hospitalizations per year) was comparable between patients aged < 50 years and those aged ≥ 70 years. Compared with patients aged 50–69 years, those aged < 50 years had a significantly higher risk of recurrent hospitalization. Longitudinal analyses demonstrated the greatest absolute declines in pre-bronchodilator forced expiratory volume in 1 s and forced vital capacity among patients aged < 50 years, with a trend toward greater FEV1 decline, whereas lung function remained relatively stable in the older age groups.

Conclusions

In this nationwide cohort, younger patients exhibited clinically meaningful disease activity, including recurrent hospitalization and greater longitudinal lung function decline, despite fewer comorbidities and better baseline lung function. These findings underscore the heterogeneity of bronchiectasis and suggest that younger age does not necessarily indicate a benign disease course.